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Abstract 
Use of the ketogenic diet in cancer patients is currently being explored in all stages and 
types of cancer. The ketogenic diet could influence human metabolism in such a way as to 
reduce tumor growth, increase efficacy of standard cancer treatments, and reduce side effects of 
those treatments. The goal of this review was to examine the available evidence on the effects of 
the ketogenic diet in human cancer patients. Including the only randomized controlled trial to 
date, 15 articles were reviewed and summarized to help determine the state of the science. As 
research in this area is emerging, most of these studies used small sample sizes and were 
conducted in patients with advanced cancer stages. However, they differed in design, diet 
intervention, and measurement of outcomes, including method and frequency of biomarkers and 
diet adherence. Although most results from these studies are mixed, all studies support the safety 
and feasibility of the ketogenic diet for cancer patients. Those studies that examined body 
composition reported positive effects from the ketogenic diet, such as preservation of muscle 
mass and increased physical functioning. In addition, certain biomarkers point to a positive effect 
of the diet on cancer proliferation; however, it is unknown if the effects of the diet differ between 
specific cancer cell types and if these effects influence tumor growth. More research is needed to 
elucidate the mechanisms behind the effects of the diet, and to determine the differences in 
metabolism across specific cancer cell types before this diet can be recommended. 
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Introduction 
Despite improvements in early detection and treatment, cancer is still the second leading 
cause of death worldwide (1,2), and approximately one in six individuals will be diagnosed with 
cancer in their lifetimes (2). The ketogenic diet is currently being explored for use in people with 
all types and stages of cancer with or without standard treatments such as radiation, 
chemotherapy, or immunotherapy. Though the ketogenic diet was developed as a treatment for 
epilepsy in children (3,4), it has potential be helpful for cancer due to the biochemical effects of 
the diet on human metabolism (5–11).  
The ketogenic diet intends to mimic the state of fasting by severely restricting 
carbohydrate intake in order to induce ketosis (4). During times of fasting, and thus while 
following the ketogenic diet, ketones are produced from fatty acid degradation providing healthy 
cells with an alternative energy source, thereby reducing the need for glucose. The classic 
ketogenic diet is composed of a 4:1 ratio of grams of fat to carbohydrate plus protein (90% of kJ 
or calories from fat, 6% from protein, and 4% from carbohydrate). Since this distribution of 
macronutrients does not meet the protein requirements for most adults (12), a more liberal diet is 
often used, such as a 3:1 gram ratio (82% of kJ or calories from fat, 12% from protein, and 6% 
from carbohydrate) or the modified Atkins diet (3). The modified Atkins diet is a 0.8:1 ratio of 
grams of fat to carbohydrate plus protein (65% of kJ or calories from fat, 30% from protein, and 
5% from carbohydrate, with less than 20 grams carbohydrate per day for adults) and has been 
found to be more feasible and sustainable in adults while still allowing ketosis (3,13–15). 
Given the potential of the ketogenic diet to improve outcomes in cancer patients, research 
is emerging in both animals and humans. Animal studies have shown promise for the ketogenic 
diet to attenuate tumor growth, reduce muscle wasting, and sensitize various tumor types to 
traditional treatments (16–21). However, some animal studies have shown tumor progression in a 
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specific cancer type while on the ketogenic diet (the BRAF V600 positive melanoma model) 
(22). In another animal study, metastasis was observed when exogenous ketones were 
administered to mice with breast cancer xenografts (23).  
In humans, the ketogenic diet could reduce blood glucose levels, limiting fuel availability 
to cancer cells since these cells may not be able to efficiently use ketones for energy (5–11). The 
diet may also inhibit growth signals due to the low amount of carbohydrate consumed on the diet 
(5–11). Therefore, the ketogenic diet could affect cancer in three ways: 1) the diet could reduce 
tumor growth, 2) it could increase the efficacy of standard cancer treatments by inhibiting 
production of endogenous antioxidants generated from increased glycolysis, and 3) it could 
reduce or prevent treatment-limiting and potentially life-threatening side effects, such as muscle 
wasting or cachexia (5–11) (i.e., multi-factorial sarcopenia with weight loss typically more than 
5% of usual body weight) (24). Pre-clinical trials support these benefits, but the effectiveness of 
the ketogenic diet must be further evaluated in human cancer patients before it can be provided 
as a viable treatment option.  
Despite these potential benefits, few studies have focused on the ketogenic diet in human 
cancer patients; therefore, this review presents the available relevant studies on this topic. While 
systematic and narrative reviews of the ketogenic diet in cancer patients have been conducted, 
they have been broad in scope, including individual case reports (9,25–29), interventions other 
than a ketogenic diet (25,28,30), or only one cancer type (28). Two studies also included 
pediatric patients (27,29) who may exhibit different metabolism and responses to dietary 
interventions than adults (31). To date, previous reviews have not included randomized 
controlled trials of the ketogenic diet in cancer. Thus, the following review aims to examine the 
current state of the science on the effects of the ketogenic diet in cancer patients and to help 
identify important objectives for future research.  
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Methods 
A literature search was conducted on September 22, 2018 and included all papers 
published until this date. Two databases were used, PubMed and Web of Science, to search for 
studies involving the ketogenic diet in human cancer patients. Search terms were formulated with 
help of a librarian and included variations of ketogenic, ketones, or modified Atkins and cancer, 
tumors, or neoplasms using Boolean terminology. The exact search terms for each database can 
be found in Appendix A. Criteria for inclusion were studies relating the use of a ketogenic diet or 
modified Atkins diet with adult human cancer patients while in treatment, after treatment, or as 
sole treatment. Papers in a language other than English were excluded, as were in vitro studies or 
studies using solely animals. In order to describe the current state of the evidence, this review 
includes all studies from the search that evaluated the use of the ketogenic diet in cancer patients, 
with the exception of individual case reports. Since case reports are important to help inform 
future studies but are not sufficient to determine generalizable outcomes for specific treatments 
(32), these were not included. 
Titles and abstracts of all papers resulting from the search were reviewed. Those papers 
that did not meet inclusion criteria were removed. The remaining articles were read in full; again, 
excluding those that did not meet the inclusion criteria. Additional qualifying articles were 
identified from reference lists of included papers and others used for background research. Data 
abstracted from these studies include: study design, country, cancer type, concurrent cancer 
treatments, age, sex, race, number of participants, length and details of the dietary interventions, 
if and how ketosis was measured, adverse events, and primary and secondary outcomes.  
 
Results 
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The search in PubMed resulted in 176 articles, which was further reduced to 149 articles 
after excluding articles that were not in the English language or human studies. The Web of 
Science search resulted in 176 articles. Of these combined 325 articles, four were duplicates and 
removed. Of the remaining 321, ten articles met the inclusion criteria. Five additional articles 
were included from papers used for background research. In total, 15 articles were included in 
this review.  
 
Figure 1: Flowchart of literature selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study characteristics 
Study characteristics and outcomes are detailed in Table 1 and major points are discussed 
in the following sections. The 15 articles that comprise this review were published between 1988 
and 2018. Study designs include one randomized controlled trial (33,34); one non-randomized, 
three-arm controlled trial (35); one observational case series (36); one observational pilot (37); 
325 papers identified from PubMed and Web of Science 
321 abstracts screened against inclusion criteria 
4 duplicates excluded 
25 full text articles screened against inclusion criteria 
14 articles excluded: 
-8 hypothesis, theory, reviews  
-3 not ketogenic diet 
-1 pediatric 
-1 animal study 
-1 ongoing trial 
15 articles included in final review 
10 articles met criteria 5 articles added from reference lists 
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and one retrospective review (38). Two studies utilized cross-over trials (39,40) and three were 
single-arm pilot studies (9,34,35). Four studies were single-arm clinical trials (14,15,43,44), two 
of which used retrospective data (43) or study drop-outs for comparison (44). Studies were 
conducted mostly in Germany (n=5) and the U.S.A. (n=5). Race was only reported in three 
studies. Two included all (14) or majority (33) Caucasian participants, while one included an 
equal number of Caucasian and African American participants (41). 
Across 14 studies, 156 participants attempted the ketogenic diet. Study participant age 
ranged from 30-78 years. Participants in nine studies had advanced cancer (14,15,17,36–
38,40,41,43), while in four studies, cancer stage ranged from early to advanced (33,35,42,44). 
One study did not report cancer stage, but all patients were considered cachectic, with 32% mean 
weight loss and anorexia pre-study (mean energy and protein intake was 55% and 28%, 
respectively, of estimated needs) (39). Six studies included various cancer sites 
(14,36,37,39,41,42). Of the studies that focused on single cancers, most included glioblastomas 
or other brain cancers (15,17,38,43), while the rest included gastrointestinal (35), head and neck 
(40), lung and pancreatic (44), and endometrial and ovarian cancers (33). Radiation, 
chemotherapy, or immunotherapy were concurrent treatments in seven studies (15,17,33,38,42–
44), while four used the ketogenic diet as sole therapy (14,35,37,41). Three studies did not report 
concurrent treatment status (14,37,41). Of the studies that used the ketogenic diet as sole 
treatment, three were administered in metastatic or previously treated patients who had no further 
treatment options (14,37,41). The other was administered in patients of varying cancer stages 
who were treatment naïve, shortly before surgery (35).  
 
Measurement of Ketosis 
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Ketosis was measured in eleven studies (14,15,17,33,37–39,41–44), however, each used 
different criteria. Ketone levels used to determine ketosis ranged from “detectable” to ≥ 4 
mmol/l, and studies varied in the frequency of measurement and the vehicle used for analysis 
(i.e., blood, urine, or both). Urine ketones alone were measured in three studies (15,17,37), while 
three studies only measured blood ketones (14,39,41). Four studies measured both blood and 
urine ketones (33,38,42,44). One study measured both urine and brain ketones (43). Frequency 
of measurement varied from twice per day to every four weeks. One study used ketosis as a 
measure of dietary adherence and determined that one of five participants did not adhere to the 
diet, while two adhered intermittently, and two adhered strictly (43). Two studies reported 
dietary adherence in participants that did not achieve ketosis (17,42). Another assessed dietary 
adherence by both dietary recall and ketone levels, and reported that 80% of the participants had 
achieved dietary adherence (33). 
 
Intervention 
The intervention evaluated in all studies was a carbohydrate restrictive diet, although the 
specifics differed in each. The diet composition ranged from 4% of total kJ or calories per day 
from carbohydrates to as much as 16% (39). Intervention times ranged from five days to 12 
months; the most frequent length was 12 weeks. Most commonly, participants were responsible 
for purchasing groceries and preparing meals that adhered to the diet. Education and support in 
the form of dietary counseling and meal plans from a registered dietitian or physician were 
provided in ten of the 14 studies (14,15,17,33,36–38,41–43). Three interventions were patient-
directed using available resources on the ketogenic diet (36,38,42). One study (44) prepared and 
provided all the meals, while two studies had controlled delivery via nasogastric tube (39) or 
parenteral nutrition (35). One study did not discuss details of the intervention (43). No study 
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reported providing behavioral counseling or skills training to assist participants in changing their 
diet, although one indicated that frequent counseling by a registered dietitian, ketogenic formulas 
and meals, and cooking classes would be of benefit for future patients (42). 
 
Primary Outcomes 
Safety and feasibility 
Because the study of the ketogenic diet for cancer patients is in its infancy, the majority 
of studies measured safety and feasibility as primary outcomes (n=9) (14,15,17,37–39,41,42,44). 
One measured feasibility as the ability of the participants to achieve ketosis (defined in this study 
as serum levels > 0.2 mmol/l) and was successful in all five participants (39). Seven studies 
measured feasibility by the number of participants who withdrew (15 out of 89) because of diet 
intolerance, side effects, or inability to follow the prescribed diet (14,15,17,37,41,42,44). 
 Six studies measured feasibility by monitoring adverse events; the most common were 
mild constipation (15,37,41,44), mild to moderate fatigue, nausea, and bloating (14,37,38,41). 
Two studies withdrew three participants due to hyperuricemia, dehydration (44), and “excessive” 
weight loss and weakness (37). One study reported no significant difference in quality of life 
scores before the diet and after the diet (14), while another reported a slight improvement in 
insomnia and emotional functioning, while other parameters declined slightly (37). 
One study examined the possibility of future clinical trials of the ketogenic diet in people 
with brain cancer (15). Four of six participants who had completed a 12-week trial of the diet 
reported they would participate in another clinical trial, while only one would do so if the trial 
was randomized. A separate poll of 172 persons with brain cancer who had not participated in 
the study found that 66% would be willing to participate in a future clinical trial, but only 36% 
would do so if the trial was randomized (15). Another study that polled its participants found that 
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while three of six thought the diet was difficult, all felt “good” or “very good” on the diet, and 
continued a variation of a low-carbohydrate diet after the study ended (42). 
  
Metabolic effects  
Metabolic effects of the ketogenic diet were reported as primary outcomes in eight 
studies (35,36,38–41,43,44). In one crossover trial, blood glucose was reduced by a mean of 14% 
after 7 days of the ketogenic diet (39), and by a mean of 58% in a retrospective review with diet 
adherence ranging from three to twelve months (38). However, 14 days of parenteral 
administration of the ketogenic diet resulted in no significant difference in blood glucose (35). 
Similarly, serum lactate and pyruvate, byproducts of glucose metabolism, decreased by 
46% and 40%, respectively, after administration of the ketogenic diet in Fearon et al.’s crossover 
trial (39). Lactate levels in tumor tissue also declined from baseline by a range of 0.16 to 3.73 
mmol/l in tumor tissue in head and neck cancer patients after five days of the diet (40). 
Jansen and Walach (36) measured reduced levels of transketolase-like-1 (TKTL-1) (-150 
mean change in EDIM-TKTL-1 scores), an oncogene marker that is associated with enhanced 
glucose metabolism, proliferation, and poor prognosis (45). Zahra et al. (44) discovered 
significant increases in mean carbonyl levels by 0.4 nmol/mg compared to baseline levels in 
participants on the ketogenic diet, a measure of increased oxidative stress. 
Insulin level was a primary outcome for two studies (39,41). Fine et al. (41) found that 
ketone levels ranging 10 to 35 times higher than baseline were associated with 70% to 90% 
reduction in serum insulin levels. However, insulin levels and insulin-like growth factors (IGF-1 
and IGF-2) were found to have no significant association in a study of 10 patients (41). Fearon et 
al. (39) found no significant difference in insulin levels between a normal diet and the ketogenic 
diet, even though blood glucose was reduced.  
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Artzi et al.’s study (43) attempted to determine if brain tissue utilizes ketones and if urine 
was an accurate way to measure ketosis. While all five participants had achieved at least 
intermittent ketosis as assessed by urine level, ketones were only detected in brain tumor tissue 
once out of 27 total scans and in tumor-free tissue in three scans in two patients.  
Anthropometrics    
 Three studies reported anthropometrics as primary outcomes (33,35,42), two of which 
noticed significant loss of fat mass with preservation of muscle mass (33,42). Using dual-energy 
X-ray absorptiometry (DXA), Cohen at al.’s randomized controlled trial showed that ketogenic 
dieters lost significantly more fat mass than controls (5.2 kg versus 2.9 kg), with no significant 
difference in loss of lean muscle mass (33). A prospective trial (42) showed significant increases 
in relative fat free mass of 0.29% to 0.49% per week in three of four measurable participants 
using bio-electrical impedance analysis (BIA). However, Rossi-Fanelli et al. (35) found no 
difference in muscle or fat mass from baseline in either the lipid or carbohydrate arms after a 14-
day intervention.  
Tumor progression 
 Only one study measured tumor progression as a primary outcome. Rossi-Fanelli et al. 
(35) measured tumor proliferation using thymidine sampling and found a non-significant trend in 
an increase (32.2%) of replicating cells in participants receiving 100% dextrose parenterally, and 
a non-significant decrease (-24.3%) in participants receiving 80% lipid solution.  
 
Secondary Outcomes 
Tumor progression and survival 
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Though no study was powered to determine the efficacy of the diet on disease status, nine 
studies included some measure of tumor progression or survival as a secondary outcome, 
attributing observed effects to various reasons (14,17,36–38,41–44).  
One observational study demonstrated an association between decreased tumor 
progression and adherence to the diet as determined by dietary recall (ketones were not 
monitored) (36). Another found that those with stable disease had the longest diet adherence, and 
some participants who had achieved ketosis had progression of disease (37). A prospective study 
found that participants who adhered to the diet, but had low levels of ketones, showed partial 
tumor regression (42). However, ketosis was associated with greater overall survival in three 
studies (17,38,41), one which found three-fold higher ketone levels in participants with partial 
remission of glioblastoma than in those with progressive disease (41). One study found positive 
tumor responses among dieters with the greatest weight loss (10% or more), but no difference in 
levels of ketosis or blood glucose in those that had stable disease or partial remission and those 
that had progressive disease (14). In contrast, two prospective studies showed no effect of the 
diet on tumor progression or on progression-free survival (43,44). 
Metabolic effects 
Eight studies reported biochemical markers as secondary outcomes 
(14,15,17,33,37,40,42,44). In a randomized controlled trial, Cohen et al. (33) found higher levels 
of ketosis inversely associated with serum insulin levels and IGF-1, but did not find significant 
differences in IGF-1 or its binding protein (IGFBP-1) between those following a ketogenic diet 
and controls. 
Four studies (14,18,32,42) found no significant difference in blood glucose levels from 
baseline after the diet. Zahra et al. (44) found mixed results, but one study reported 
improvements in blood glucose levels (37), and another reported decreased amplitude of blood 
The Ketogenic Diet for Cancer Patients  
 
13 
 
glucose from the diet (40). One study showed a negative correlation with serum ketone and 
glucose levels (42). No other studies reported significant differences in any biomarkers.  
Anthropometrics 
In seven studies reporting weight changes as a secondary outcome 
(14,15,17,37,39,41,44), all but one (39) reported weight loss (ranging from 2% to 10%). The 
only study that resulted in weight gain included cachectic patients who were fed isocaloric 
regular and ketogenic diets for seven days each, but showed an average weight gain of 2 kg only 
after administration of the ketogenic diet (39). Only one of these seven studies showed no 
significant difference in weight, fat mass, or arm circumference between pre- and post-diet (15). 
Physical Functioning 
Physical functioning was reported as a secondary outcome in three studies. Two studies 
reported improvements in physical functioning post-ketogenic diet (34,39), while a third found 
no difference between baseline and study completion (44). 
 
Discussion  
Studies conducted thus far support further research into the efficacy of the ketogenic diet 
for cancer patients. With the support of biochemical theory, in vitro, and animal studies, trials in 
cancer patients have begun to test the safety, feasibility, and effects of this diet. While difficult 
for some to follow, the majority of patients in the studies included in this review (141 out of 156) 
were able to adhere to the diet for the study period. The majority of withdrawals occurred at four 
to eight weeks, though patients in three studies followed the diet for one year or longer 
(36,38,43). While adherence to the diet likely depends on several factors such as treatment side 
effects and individual preferences, adherence for at least four weeks suggests that use of the 
ketogenic diet concurrently with standard cancer treatments is feasible for patients. Generally 
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unchanged or improved biomarkers demonstrate that the diet is safe and has potential to be 
beneficial for cancer patients.   
With the exception of one study (44), this review found that the ketogenic diet has the 
potential to reduce or even reverse the muscle wasting that often accompanies cancer and 
standard cancer treatments (17,33,39,42). One of the main nutrition concerns for a cancer patient 
undergoing treatment is rapid weight loss because this usually indicates loss of muscle mass, 
undermining the patient’s treatment, quality of life, and even survival (7). Most of the studies 
monitored weight changes, but only four (17,33,39,42) measured muscle mass or protein 
turnover. Cohen et al. (33), reporting on the only randomized controlled trial to measure the 
effects of the ketogenic diet on body composition to date, demonstrated loss of fat mass with 
preservation of muscle mass in patients following the ketogenic diet as compared to the control 
group. Future studies would benefit by including measurements of fat-free mass or physical 
functioning to better understand the ketogenic diet’s effect on body composition. There is 
evidence that in a cachectic patient, the number of calories consumed may not have a direct 
effect on weight (39,46), pointing to the potential metabolic alterations taking place in some 
cancer patients. Addressing these changes through diet composition may be of benefit, as seen in 
Fearon et al.’s study of cachectic patients (39).  
Along with the reduction of muscle wasting, studies showed that the ketogenic diet is 
associated with reduced blood glucose and metabolites of aerobic glycolysis and 
gluconeogenesis, namely pyruvate, lactate, and TKTL-1 (36,39). These markers are indicative of 
reduced cancer cell activity and show promise for a positive effect of the ketogenic diet on tumor 
growth. However, these were small sample sizes with short intervention duration, and few 
studies measured these outcomes. Additionally, the progression-free survival and overall survival 
of the patients included in these studies do not show a clear influence of the ketogenic diet on 
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tumor progression. Studies that reported positive effects on tumor growth attributed these to 
various reasons: the intervention diet (36,37,42), the level of ketosis (17,38,41), the amount of 
weight loss while on the diet (14), or an immunotherapy drug (43). Future studies would benefit 
from establishing a standard of monitoring ketosis, byproducts of glucose metabolism, and diet 
adherence in order to better understand the mechanism behind the effects of the diet.  
The ability of the ketogenic diet to improve the efficacy of cancer treatments by 
increasing oxidative stress while reducing endogenous antioxidants remains to be seen in 
humans. While one study tested this theory and found elevated carbonyl levels as a marker of 
increased oxidative stress in three dieters undergoing radiation and chemotherapy or 
immunotherapy (44), more evidence is required to support this theory in cancer patients. 
Although not the goal of these interventions, the majority of participants who followed 
the ketogenic diet experienced weight loss. Only five of eleven studies with participants 
responsible for their own meals reported gathering dietary recalls (15,33,41–43), while only two 
reported the caloric intake of participants (41,42). Collecting food diaries or dietary recalls 
would be beneficial in future studies to help differentiate effects from spontaneous calorie 
reduction, as occurred in Fine et al. (41), or from diet composition, as seen with Fearon et al. 
(39). 
The strengths of this review lie in the systematic approach used and the clinical lens 
through which study outcomes were viewed. Any benefit of the ketogenic diet for the cancer 
patient must be considered. While the results of this review point to the appropriateness and 
benefit of further study of the ketogenic diet for cancer patients, the finding should be considered 
in the context of some limitations. Although the literature search was conducted with only two 
databases, a systematic approach was used with consultation from a librarian with expertise in 
systematic reviews. While five qualifying articles were not included in the initial search results, 
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additional papers were identified for inclusion by searching reference lists of articles resulting 
from the search.  
An in-depth critique of cancer cell types and results from animal studies was beyond the 
scope of this review but warrants further examination. Studies of specific cancer types in animal 
models have demonstrated tumor growth and metastasis with administration of the ketogenic diet 
or exogenous ketones (22,23). In addition, it is unclear if specific cancer cell types may be able 
to use ketones for energy, as ketones have been detected in brain tumors of both animals and 
humans (43,47). Future larger trials that are adequately powered to evaluate the efficacy of the 
ketogenic diet are warranted. However, these studies would benefit from a more detailed 
evaluation of the metabolism of different cancer cell types to further elucidate the potential 
harms and benefits from the implementation of the ketogenic diet in cancer patients.  
In conclusion, the results from this review support further study into the effects of the 
ketogenic diet in cancer patients. There are at least 16 clinical trials underway studying the 
ketogenic diet and various cancer types, including brain, breast, prostate, endometrial, 
lymphoma, and one on body composition (48). The diet holds promise as an adjuvant treatment 
to reduce muscle loss, improve tolerability of concurrent therapies, and improve quality of life. 
However, clarity about the effects of the diet on specific cancer types, as well as results of safety 
and efficacy from larger studies, are necessary before the ketogenic diet can confidently be 
recommended as a viable option for cancer patients.  
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Table 1: Study characteristics                                
Author/ 
date/ 
country 
Study design # analyzed Cancer 
type/stage 
Mean 
age 
Sex Race Length of 
intervention 
Intervention/ 
implementati
on 
Concurrent 
treatment 
How 
study 
measured 
ketosis 
# who 
attained  
ketosis 
Adverse 
events 
Primary 
endpoint 
measured 
Primary 
outcome(s) 
Secondary 
outcome(s) 
Rieger et al. 
(17), 2014  
 
Germany 
Single arm 
prospective 
pilot  
13 measured 
urine ketones 
 
20 enrolled 
17 evaluated 
Recurrent 
glioblastoma 
 
Advanced 
disease 
57 
median 
 
30-72 
range 
65% F Not 
reported 
12-16 
weeks (up 
to 124 
weeks f/u) 
KD: ≤60g 
CHO/day  
No calorie 
restrictions 
Yogurt/oil 
drinks 
provided 
(500ml/day). 
 
Diet 
education, 
recipes, food 
facts, and 
rules were 
provided 
 
Participants 
prepared 
meals at 
home, no 
eating plans 
provided  
Bevacizumab 
(n=7) 
Steroids 
(n=11) 
Urine  
 
Ketones 
detectable 
in ≥50% 
measurem
ents 
 
Tested: 2-
3 x week 
8 achieved 
“stable” 
ketosis 
(ketones 
detected 
≥50% of 
the time) 
 
5 achieved 
ketosis 
<50% of 
the time  
 
Hunger, 
sugar craving 
in first week 
 
Diet 
intolerance: 3 
 
Feasibility-% 
discontinued 
diet due to 
intolerability 
15% (3/20) 
discontinued 
diet due to 
“negative 
effects on 
quality of life” 
 
 
Mean 2.2% 
weight loss 
 
NSD in BG, 
chol. LDL, 
HDL, TG 
 
Median PFS: 6 
wks for stable 
ketosis (n=8) 
3 wks w/o 
stable ketosis 
20 wks for 
bevacizumab + 
diet 
 
Overall 
median 
survival: 32 
weeks from 
enrollment 
(n=17)   
Artzi et al. 
(43), 2014 
 
Israel  
Single arm 
prospective 
cohort with 
retrospective 
data used for 
comparison 
9 (5 dieters, 4 
GB 
retrospective 
controls) 
4 with GB 
(advanced  
stage), 1 with 
gliomatosis 
cerebri (low 
grade) 
51 56%  F Not 
reported 
2 months to 
>31 months  
 
3 yrs on 
diet for 
gliomatosis 
cerebri 
KD: 4:1 ratio 
based on 
KetoCal 
powdered 
formula. 
Specific diet 
plan was 
tailored to 
each 
participant 
Bevacizumab 
+ steroids for 
GB 
 
KD only for 
gliomatosis 
cerebri 
 
Comparison 
group: TMZ, 
BVZ, or 
rindopepimut 
Urine 
Ketones 
>2 (units 
not 
indicated) 
 
Tested: 
daily  
 
H-MRS: 
every 2 
months 
 
Urine: 4 
achieved 
high 
ketoses 
(>4) 
 
H-MRS:  
detected in 
2 
participants  
Intermittent 
diet 
compliance: 
2  
 
Diet 
intolerance: 1  
Metabolic 
brain changes 
using H-
MRS 
Ketones 
detected in 
brain 4 times 
in 2 patients (3 
in one – 2 in 
NAWM, once 
in lesion), 1 in 
other- in 
NAWM) 
 
No association 
of urine ketone 
level and brain 
ketones 
SD in one 
patient with 
low grade 
gliomatosis 
cerebri 
 
PR or SD in 3 
GB patients 
after 2 months 
(attributed to 
immune 
therapy) 
Cohen, 
Fontaine, 
Arend, 
Alvarez et 
al. (33), 
2018 
 
Cohen, 
Fontaine, 
Arend, 
Soleymani 
et al. (34), 
2018 
 
U.S.A. 
RCT w/ 
parallel arm 
45 (20 ACS; 
25 KD) 
Endometrial, 
ovarian, 
various 
stages 
ACS: 
58.6 
KD: 
61.5 
 
 
100% 
F 
Cauc/ 
AA/ 
Asian 
 
ACS: 
17/3/0  
 
KD:  
22/2/1 
12 weeks KD: 70:25:5 
fat: protein: 
carbohydrate 
 
Control: 
ACS diet 
(high fiber, 
low fat) 
 
Participants 
responsible 
for meal 
preparation  
RD provided 
Individual 
diet 
education, 
weekly 
counseling, 
recipes and 
meal plans 
25% (11) 
were 
receiving 
chemo, type 
not reported 
Urine 
Ketones 
>0.5 
mmol/L  
 
Tested: 
First 2 
weeks: 
daily 
remaining 
10 weeks: 
weekly 
Serum 
BHB at 
baseline 
and 12 
weeks 
20 KD 
participants 
(80%) 
 
 
KD: 
Constipation, 
mild fatigue  
 
Unable to 
adhere to diet 
ASC: 2 
KD: 1  
 
Body 
composition 
(measured 
with DXA) 
KD: Greater 
total (5.2 kg vs 
2.9 kg) and 
visceral fat 
loss (177 g vs 
126 g) 
 
NSD in lean 
muscle mass 
loss 
KD vs ACS: 
Lower serum 
insulin (6.7 
uU/mL vs 12.1 
uU/mL, 
p<0.01), c-
peptide (2.0 
ng/mL vs 3.0 
ng/mL, 
p<0.001) 
 
NSD in blood 
glucose 
 
Higher BHB 
(0.91 mmol/L 
vs 0.25, 
p<0.001) 
NSD for IGF-
1, IGFBP-1 
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Increased 
physical 
functioning 
(Medical 
Outcomes 
Study Short 
Form-12 
Health Survey) 
reduced starch 
and fat 
cravings (Food 
Cravings 
Inventory) 
increased salt 
cravings 
(Visual Analog 
Scale for 
Appetite) 
 
NSD in mental 
functioning or 
appetite 
Fearon et 
al. (39), 
1988 
 
U.K. 
Non-
randomized 
crossover 
trial  
 
Subjects as 
own controls 
5 lung (2), 
ovarian (1), 
gastric (2) 
All 
considered 
cachectic, 
staging not 
reported 
61  60% F Not 
reported 
14 days KD (days 7-
14): 70% 
MCT, 14% 
protein 
 
Regular diet 
(days 0-6): 
55% CHO, 
31% fat 
 
Tube feeds 
provided 
Not reported >0.2mmol
/L serum 
acetoaceta
te + BHB 
 
Tested: 
every 
other day 
during 
KD 
5 within 24 
hours of 
KD 
None 
reported 
Ketosis, BG, 
nitrogen- 
balance, 
concentration 
of GNG 
substrates 
KD: ketones in 
all 
>0.2mmol/L 
 
BG: 14% 
decrease 
 
Pyruvate: 40% 
decrease 
 
Lactate: 46% 
decrease.  
 
NSD in LFT, 
FFA, 
glutamine, N-
balance, BUN, 
creatinine, 
whole body 
protein 
turnover 
 
NSD in insulin 
levels (14.3 vs 
15.3 uU/mL, 
p>0.1) 
2 kg mean 
weight gain 
after KD 
 
Increase 1 
grade in 
performance 
scale (WHO) 
after KD 
Zahra et al. 
(44), 2017 
 
U.S.A. 
Phase 1 
prospective 
clinical trial  
 
Used 
dropouts for 
comparison 
9 enrolled, 6 
withdrew 
3 evaluable 
NSCLC 
(n=2): stage 
III-IV; 
pancreatic: 
(n=1), stage 
Ia-III 
67.5 100% 
F  
 
  
Not 
reported 
Lung: 42 
days (n=2) 
Pancreas: 
34 days 
(n=1)  
5-6 weeks 
intended 
KD (4:1) 
90:8:2 ratio 
for fat: 
protein: 
carbohydrate 
 
Meals 
provided for 
participants 
lung: 
carboplatin + 
paclitaxel + 
radiation  
 
pancreas: 
gemcitabine 
+ radiation 
 
≥0.6mg/dl 
Urine 
ketones 
and serum 
ketones   
 
Tested: 
daily 
finger 
stick 
blood, 
3 See primary 
outcomes 
Tolerability  
(Common 
Terminology 
Criteria for 
Adverse 
Events 
version 4.0), 
carbonyl 
levels  
Lung: 4 
dropped out 
due to 
difficulty 
adhering to 
diet, 
constipation, 
fatigue, 
bloating, 
nausea 
 
NSD in weight 
change in 
dieters and 
drop-outs 
 
Mean weight 
loss for lung: 
6%  
Mean weight 
loss for 
pancreas: 10% 
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weekly 
venous 
serum 
1 with dose-
limiting grade 
4 
hyperuricemia 
 
Pancreas: 1 
with dose-
limiting grade 
3 dehydration 
 
Carbonyl 
levels: 
increased from 
1.0-1.4  
nmol/mg   
 
 
BG: increased 
in NSCLC 
(~30 mg/dl), 
decreased 
slightly in 
pancreas (~1 
mg/dl) 
 
Karnofsky 
performance 
status not 
improved with 
KD 
 
NSD in PFS 
between 
dieters and 
drop-outs. 
 
Median 
survival of 
drop-outs: 22 
months 
Median 
survival of KD 
dieters: 17.7 
months 
Fine et al. 
(41), 2012 
 
U.S.A. 
Prospective 
pilot 
10 (9 had 
pre-existing 
progressive 
disease) 
Varied: 
breast (2), 
lung (2), 
colorectal 
(3), fallopian 
tube (1), 
esophagus 
(1), ovary 
(1); 
Advanced, 
incurable 
63 70% F 4 AA         
4 Cauc. 
1 Asian         
1 
Hispanic 
26-28 days Goal: 5% 
carbohydrate 
Actual: ~9% 
carbohydrate 
 
Participants 
required to 
purchase and 
prepare 
meals. 
Provided 
with 
instructions 
and menus 
None Serum 
BHB tests 
compared 
to 
baseline 
as a 
measure 
of insulin 
inhibition 
 
Tested: 
weekly 
All 10 
achieved a 
mean 
ketone level 
above 
baseline 
See primary 
outcomes 
Adverse 
events,  
insulin levels 
 
Common 
Terminology 
Criteria for 
Adverse 
Events, 
version 3.0 
used 
Grade 2 
fatigue (n=5), 
grade 1 
constipation 
(n=5) grade 1 
leg cramps 
(n=1 
reversible) 
 
Ketosis 
inversely 
associated with 
serum insulin 
levels 
(regression 
coefficient =  
-1.67, 
p=0.026) 
 
NS association 
of insulin 
levels and 
IGF-1 and 
IGF-2 
(regression 
coefficient -
0.10, p=0.38 
and -0.17, 
p=0.21, 
respectively) 
 
2.5%-6.1% 
weight loss in 
9/10 
participants 
(mean 4%) 
 
All had ~35% 
unintentional 
calorie 
reduction 
 
No difference 
in caloric 
intake or 
weight loss in 
PD and SD or 
PR   
 
PD: n=4  
SD: n=5  
PR: n=1  
SD and PR had 
3-fold higher 
ketone levels 
than did PD 
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NSD in BG, 
electrolytes, 
renal function 
 
Martin-
McGill et 
al. (15), 
2018 
 
U.K. 
Single arm 
prospective 
trial for 
service 
evaluation 
6 (4 
completed 
study) 
High-grade 
glioma with 
prior surgical 
resection, 
stages III-IV 
 47.5 100% 
M 
Not 
reported 
12 weeks Modified 
KD: 70% fat, 
20 g 
CHO/day (3-
5% of 
calories), no 
protein 
restriction 
 
Participants 
provided 
with 7-day 
meal plan, 
diet 
literature, 
recipes, urine 
ketone sticks, 
and ketone 
diaries. Had 
contact with 
RD at weeks 
1,3,6,9,12 
TMZ, 
lomustine, 
dexamethaso
ne 
Urine 
Ketones 
≥4 
mmol/L 
Tested: 
Month 1: 
2 x day 
Month 2:  
1 x day  
Month 3: 
2 x week 
  
4 (1 had 3-
week break 
due to 
hospitalizati
on) 
See primary 
outcomes 
 
 
Tolerability 
and 
feasibility in 
NHS 
 
Patient 
willingness 
to participate 
in RCT 
2 withdrew: 1 
for dietary 
preferences, 1 
for 
deterioration 
of condition 
 
Constipation 
(n=2) resolved 
with linseed/ 
flaxseed 
 
Increase in 
grocery bill 
 
Willingness to 
participate in 
future clinical 
trial/RCT: 
From 
questionnaire 
(n=172): 66% 
(n=114)/36% 
(n=62) 
From study’s 
participants 
post trial: 66% 
(n=4)/16% 
(n=1) 
NSD in  
weight, BMI, 
fat mass, and 
arm 
circumference 
pre- and post-
diet. 
 
NS increases 
in chol, LDL, 
HDL, TG 
 
BG measured, 
not reported 
Schmidt et 
al. (37), 
2011 
 
Germany 
Prospective 
observational 
pilot 
13/16 3 
withdrew, 5 
adhered to 
diet entire 
study 
Varied, 
advanced/me
tastatic 
Ovarian 
(n=4) Breast 
(n=1) HNC 
(n=1) 
osteosarcoma 
(n=1) 
esophagus 
(n=1) 
pancreas 
(n=2) thyroid 
(n=2) colon 
(n=1) 
endometrial 
(n=1) lung 
(n=1) 
stomach 
(n=1) 
50.4 75% F Not 
reported 
12 weeks KD: ≤70g 
CHO/day 
(20g/meal) + 
2 liquid 
snacks: 250 
ml highly 
fermented 
yogurt (8mL 
vegetable oil 
mixture 10 g 
milk protein) 
 
Diet 
education, 
diet manual, 
exchange list, 
and recipes 
provided. 
Participants 
responsible 
for shopping 
and meal 
preparation 
None Urine 
Ketones 
≥0.5 
mmol/L 
in ≥50% 
of 
measurem
ents 
 
Tested: 1 
x day in 
morning 
6 (3 
dropped out 
due to 
progression 
of disease 
before end 
of study) 
See primary 
outcomes 
 
Unable to 
adhere to 
diet: 3 
 
1 dropped 
out due to 
excessive 
weight loss 
 
2 deaths 
6 PD 
Feasibility 
QoL assessed 
by EORTC 
QLQ-C30 
version 2 
Insomnia, 
emotional 
functioning 
improved, all 
other QoL 
parameters 
declined at 
least slightly 
 
Constipation, 
diarrhea, low 
appetite, N/V, 
fatigue   
 
Mean 2 kg 
weight loss 
 
Improvements 
in chol, CRP, 
BG, LFT 
Increase in 
TG, Cr 
(WNL).  
BG: mean 103 
mg/dl 
(baseline) to 
mean 93 mg/dl 
(end of study) 
 
Reduced 
albumin 
(WNL) 
 
PD: 3 (w/ 
ketosis) 
withdrew  
 
SD: 5 (adhered 
to diet entire 
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study, 3 w/  
ketosis) 
Tan-
Shalaby et 
al. (14), 
2016 
 
U.S.A. 
Single arm 
prospective 
trial 
11/17  
(4 completed 
study) 
Varied, 
advanced 
Bile duct 
(n=1) 
Glioblastoma 
(n=1) 
Astrocytoma 
(n=1) 
Prostate 
(n=1) 
Melanoma 
(n=3)  
Renal (n=1) 
Colon (n=1) 
HNC (n=2) 
Liver (n=1) 
Pancreas 
(n=1) 
Lung (n=2) 
 
 
65 100% 
M 
Cauc. 16 weeks MAD: 20-40 
g CHO/ day 
no kcal or 
protein 
restrictions 
 
Advice on 
grocery 
shopping and 
menu 
planning 
provided  
None Serum 
Ketones 
detected 
 
Tested: 
every 4 
weeks  
All 11 
Ranges: 
0.28-4.13 
mmol/L 
Weight loss- 
mean 7.3 kg 
(7.7%) (n=8 
of 11) 
Hyper-
uricemia 
(n=7 of 11) 
 
Hyperlipide
mia, pedal 
edema, 
anemia, 
pruritis, 
hypoglycemi
a, hyper- and 
hypokalemia, 
hypomagnese
mia, fatigue, 
flu like 
symptoms 
(n=2 of 11) 
 
Unable to 
adhere to 
diet: 1 
Safety and 
feasibility 
assessed by  
EORTC 
QLQ-C30 
version 3 
NSD in QoL 
scores between 
baseline and 
end of study 
10% weight 
loss, decrease 
in BMI 
 
NSD in any 
serum values 
from baseline 
(day 2) (BG, 
chol, HDL, 
LDL, TG, 
BUN/Cr, Cr, 
albumin, uric 
acid) 
 
3 patients 
continued diet 
beyond study 
and 
“significantly” 
extended 
survival times 
80, 116, and 
131 weeks 
from 
enrollment 
 
Jansen and 
Walach 
(36), 2016 
 
Germany 
Systematic, 
prospective 
observational 
case series 
11 on KD 78 
total (77 had 
TKTL1 
measured)  
Breast (n=18) 
Prostate 
(n=16)  
colon (n=9) 
melanoma 
(n=2) 
lung (n=5) 
HNC (n=5) 
other (n=23)  
 
Stages 
curative 
(72%) 
palliative 
(19%) 
end stage 
(9%) 
68.3 55% 
M 
Not 
reported 
13 months Fully KD 
(n=7) 
Partial KD 
(N=6) 
No KD 
(n=65) 
As 
determined 
by dietary 
recall 
 
Participants 
instructed on 
the potential 
benefits of 
KD and 
informed 
about a 
company that 
provides 
ketogenic 
food 
products 
Not reported Not 
measured 
Not 
measured 
Not 
reported 
TKTL1 and 
Apo10 and 
tumor status/ 
progression 
KD and 
tumor status 
and 
progression 
 
 
 
Trend in 
reduction of 
TKTL1 and 
improvement 
in tumor status 
from baseline 
in those 
adhering to 
KD 
 
Probability of 
4% 
improvement 
in tumor status 
with each 
0.034 unit 
decrease in 
TKTL-1 
values 
 
No effect of 
KD on Apo10, 
no correlation 
with tumor 
status 
 
Not powered 
for 
significance 
 
 
DP: No end-
stage achieved 
“Full KD,” 1 
achieved  
“Partial KD” 
 
4 palliative pts 
adopted “Full 
KD”: 1 had 
full remission 
(metastatic 
breast), 1 had 
SD (recurrent 
breast), 1 had 
PD 
(astrocytoma, 
received 
steroids), 1 lost 
to follow-up 
 
Those who 
started KD had 
initial PR, but 
DP once 
stopped KD 
  
Significant 
correlation 
between 
adopting “Full 
KD” and 
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improvement 
in disease  
Rossi-
Fanelli et 
al. (35), 
1991 
 
Italy  
Three arm 
control trial 
27 (9 in each 
arm) 
 
GI, stages I-
IV 
(esophageal 
n=9), gastric 
(n=9), 
colorectal 
(n=9) 
39-78 
(range) 
52% 
M 
Not 
reported 
14 days Arm A: TPN, 
100% 
dextrose, 
amino acids 
0.24 g/kg 
body weight 
 
Arm B: TPN, 
80% lipid, 
20% 
dextrose, 
amino acids 
0.24 g/kg 
body weight 
 
Arm C 
(control): 
isocaloric, 
isonitrogenou
s oral diet 
 
Diet 
implemented 
parenterally 
No treatment 
prior or 
during 
Not 
measured 
Not 
measured 
No adverse 
events 
reported 
Influence of 
parentally 
supplied 
energy 
substrates on 
tumor cell 
proliferation 
and host 
nutritional 
status 
NSD in cancer 
cell 
proliferation 
between arms, 
despite trend 
for 32.2% 
increase in 
glucose arm, 
and 24.3% 
decrease in 
lipid arm 
 
NSD in blood 
glucose or 
triglycerides 
levels before 
and after diet 
in any arm 
 
Reduction in 
lymphocytes in 
both glucose 
and lipid arms   
 
NSD in 
anthropometric 
measurements 
None reported 
Klement 
and Sweeny 
(42), 2016 
 
Germany 
Prospective 
pilot 
6 Breast, 
rectum, 
prostate, 
lung, stages 
I-IV 
60 67% 
M 
Not 
reported 
Mean 48 
days (range 
32-73 days) 
0.8:1 to 1.8:1 
determined 
from dietary 
recall 
 
Self-
administered 
“KD” with 
dietary 
counseling 1 
x week and 
education 
support 
 
1 received 
ketogenic 
drinks  
Radiation/ 
chemo + 
radiation 
Urine 
ketones 
detectable 
(home)  
 
Serum (3 
x during 
study)  
 
>0.3 
mmol/L 
 
 
4 No adverse 
events 
attributed to 
diet 
Feasibility 
 
Body 
composition 
via BIA 
All lost weight 
(significant in 
2) n=4 of 6 
had reliable 
BIA indicating 
loss of FM 
(0.28 to 0.68 
kg/week) and 
stable FFM 
n=3 of 4 had 
significant 
increase in % 
FFM (0.29 to 
0.49 % per 
week) 
 
3 with 
decreased (-
0.13 to -0.15 
l/week) 1 with 
increased 
intracellular 
water (0.18 
l/week) 
 
No other 
markers of 
hydration or 
body water 
NSD in serum 
values: CBC, 
HDL and 
LDL, BG, 
insulin, IGF-1, 
TSH. 
 
Significant 
negative 
correlation 
between serum 
BHB and 
glucose 
(Spearman’s 
coefficient = -
0.035, p=0.05)  
 
Increase in 
appetite loss 
(n=3), fatigue 
(n=2), nausea 
(n=2), diarrhea 
(n=2) 
attributed to 
RT/RCT 
 
PR: n=5 
Slight PD: n=1 
(metastatic 
lung, rapid 
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changes 
(TBW, ECW) 
 
Diet analysis 
and lack of 
ketone 
measurement 
in 2 
participants 
indicate 
difficulty with 
diet adherence  
 
3 said diet was 
difficult 
 
All felt good 
or very good 
on diet 
 
All followed a 
KD or 
variation after 
treatment 
progression 
once off diet 
and completed 
treatment) 
Schroeder 
et al. (40), 
2013 
 
Germany 
Prospective 
cohort with 
participants 
as own 
control 
10/11 
evaluable (1 
male with 
equipment 
failure was 
not included 
in data) 
HNSCC, 
stage III and 
IV 
11/12 90% 
M 
Not 
reported 
5 days Not defined 
 
Implementati
on of diet not 
reported 
Not reported Not 
measured/ 
reported 
Not 
measured/ 
reported 
Not 
measured/ 
reported 
Lactate and 
pyruvate 
concentration 
in tumor and 
tumor-free 
mucosa 
3/10 pts: tumor 
lactate levels 
decreased on 
KD by 0.16 
mmol/l to 3.73 
mmol/l) 
pyruvate stable 
or increased 
 
L/P ratio was 
constant in  
tumor-free 
mucosa, 
declined in 
tumor tissue in 
7/9 
 
On KD: all pts 
showed 
decline in 
amplitude of 
blood glucose 
Champ et 
al. (38), 
2014 
 
U.S.A. 
Retrospective 
review 
Total: 53 
KD: 6 
Unspecified 
or standard 
diet: 47 
Glioblastoma 
multiforme, 
grade III-IV 
54 M/F 
(ratio 
not 
reporte
d) 
Not 
reported 
3-12 
months of 
KD. F/U up 
to 20 
months 
KD: carbs < 
50g /day to 
<30 g/day 
and limiting 
protein if not 
achieving 
ketosis. Pt-
driven diet 
but “several” 
tracked diet 
using online 
software 
 
Physician 
support 
provided if 
needed 
 
Radiation 
and TMZ 
(temozolomi
de) 
RT, cetiranib 
and TMZ 
(n=1) 
Decadron 
(n=3) 
Urine, 
serum 
 
Tested: 
Daily 
urine for 2 
weeks, 
daily 
finger 
stick, 
biweekly 
serum  
 
Ketosis 
confirmed 
by 
treating 
6 
 
Unable to 
adhere to 
diet: N/A 
Grade I 
constipation 
(n=2) 
Grade I 
fatigue (4 
during RT) 
Grade II 
fatigue with 
kcal 
restriction 
(30%) n=1 
Kidney 
stones (1 
incident) 
1 DVT 
(MTHFR 
def) 
 
Safety, BG BG 122 for 
standard diet, 
84 for KD 
(before 
treatment KD 
avg was 142.5) 
 
Wt loss: 1, 5, 
13, 27, 46 lbs 
(last 2 
intentional, 1 
on kcal 
restriction) 
 
Disease 
progression:  
At median f/u 
of 14 months: 
4 of 6 patients 
alive, 3 
patients 
recurred, 1 
patient no sign 
of recurrence 
at 12 months 
(on kcal 
restricted KD 
for 7 months, 
lost most 
weight, no 
steroids) 
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physician 
via logs 
Toxicities 
assessed 
using 
Common 
Terminology 
Criteria for 
Adverse 
Events, 
version 4 
For all pts on 
KD mean time 
to recurrence/ 
progression 
was 10.3 
months   
 
GB: glioblastoma, KD: ketogenic diet, specifics follow, BHB: beta-hydroxybutyrate, NSD: non-significant difference, NAWM: normal appearing white matter, H-MRS: proton magnetic-resonance-spectroscopy , PD: progressive disease, SD: stable disease, 
PR: partial remission, GNG: gluconeogenesis, MAD: modified Atkins diet, TPN: total parenteral nutrition 
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Appendix A: Search terms utilized per database 
 
The search term used for PubMed: “(ketogenic OR ketone OR ketones OR ketosis OR "modified 
atkins") AND (diet OR diets OR dietary OR dieting OR nutrition) AND (cancer OR cancers OR 
oncolog* OR tumor OR tumors OR tumours OR tumour OR neoplas*) AND 
((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials as topic[MeSH Terms] OR 
clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH 
Terms] OR therapeutic use[MeSH Subheading] OR "clinical trial"[tw] OR "controlled trial"[tw] 
OR "random allocation"[tw] OR randomized[tw] OR randomly[tw] OR blind[tw] OR 
blinded[tw]) NOT ("Animals"[Mesh] NOT "Humans"[Mesh])” to help capture clinical trials 
involving humans. The search resulted in 176 articles, which was further reduced to 149 articles 
using English language filters and human studies.  
 
The search term used for Web of Science: (ketogenic OR ketone OR ketones OR ketosis OR 
"modified atkins") AND (cancer* OR oncolog* OR tumor* OR tumour* OR neoplas*) resulted 
in 10,185. This was refined by using the term ("clinical trial" OR "control* trial" OR RCT), 
resulting in 147 articles.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
